Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) insider Rachel Mcminn sold 283 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.89, for a total transaction of $16,665.87. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Rachel Mcminn also recently made the following trade(s):

  • On Monday, July 31st, Rachel Mcminn sold 130 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $123.12, for a total transaction of $16,005.60.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 5.34% on Thursday, hitting $72.40. 2,882,026 shares of the stock were exchanged. The company’s market cap is $1.82 billion. Intercept Pharmaceuticals, Inc. has a 12 month low of $54.98 and a 12 month high of $156.65. The company has a 50-day moving average price of $94.11 and a 200 day moving average price of $111.08.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period last year, the business earned ($3.14) EPS. Equities analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.98) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Insider Rachel Mcminn Sells 283 Shares of Stock” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at http://www.mareainformativa.com/intercept-pharmaceuticals-inc-icpt-insider-rachel-mcminn-sells-283-shares-of-stock/117953/.

Several institutional investors have recently modified their holdings of ICPT. MARSHALL WACE ASIA Ltd purchased a new stake in Intercept Pharmaceuticals during the 1st quarter valued at about $13,012,000. Marshall Wace North America L.P. purchased a new stake in Intercept Pharmaceuticals during the 1st quarter valued at about $13,012,000. Balyasny Asset Management LLC purchased a new stake in Intercept Pharmaceuticals during the 2nd quarter valued at about $13,766,000. Macquarie Group Ltd. grew its position in Intercept Pharmaceuticals by 54.2% during the 1st quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after purchasing an additional 84,954 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares during the last quarter. Institutional investors own 82.19% of the company’s stock.

ICPT has been the topic of a number of research analyst reports. Cowen and Company restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, June 12th. Wedbush restated an “outperform” rating and issued a $231.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, June 13th. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They issued a “buy” rating and a $275.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price on the stock in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $162.88.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.